Articles related to Urology
Urinary Antiseptic Noninferior to Antibiotics for Recurrent UTI Prevention in Women
This study randomly assigned participants to receive daily, low-dose antibiotic prophylaxis (n=120) or methenamine hippurate (n=120) for 12 months. Treatment allocation was not masked, and crossover between arms was permitted. The primary clinical outcome measure was the incidence of symptomatic, antibiotic-treated UTI episodes reported by participants over the treatment period. The urinary antiseptic methenamine hippurate was found to be noninferior to prophylactic antibiotics in preventing urinary tract infections (UTIs) in women who had them repeatedly. Results were published March 9 by The British Medical Journal (BMJ).
Obstetrics & Gynecology March 22nd 2022
GU Cancer: FDA Approves Product to Increase Access to PSMA PET Imaging for Prostate Cancer
Illucix is a preparation kit for gallium-68 PSMA-11 injection, an agent indicated for PET PSMA position tumors in patients with suspected prostate cancer metastasis who are eligible for initial definitive therapy and have suspected cancer recurrence based on elevated PSA levels.
Internal Medicine January 19th 2022
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Clinical Practice Guideline
A systematic review identified 204 eligible publications from 2000 through 2017, with much of the evidence consisting of systematic reviews of observational data, consensus guidelines, case series, and case reports. Due to the paucity of high-quality evidence on management of immune-related adverse events, recommendations are based on expert consensus.
Dermatology December 21st 2021
Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
From JAMA Network Open comes this conclusion: “In this study, the benefit associated with olaparib was reduced, eliminated, or inferior in specific subgroups of patients when treatment outcomes were compared with a more active standard of care, ie, cabazitaxel. While treatment with olaparib was associated with superior rPFS in patients with BRCA1/2 variants, those with other HRR variants may have worse outcomes with this approach, which should be reassessed by national guidelines. Numerous active studies…will add to the data regarding the role of PARP inhibitors in mCRPC.”
Internal Medicine December 21st 2021
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer
Directly from this Journal of Clinical Oncology Original Report: “Among men randomly assigned to receive ADT + RT + docetaxel versus ADT + RT, significantly less RT-induced cancers were observed. The treatment effect of adding docetaxel to ADT + RT on overall survival in men with a prostate-specific antigen (PSA) < 4 ng/mL was driven by the absence of PC death, providing evidence to support a distinct biology in low PSA-producing, unfavorable-risk PC that is docetaxel-sensitive.”
Internal Medicine December 21st 2021
Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance
In this clinical trial, the authors attempt to answer the question of whether a high-intensity interval training program can improve cardiorespiratory fitness and delay the biochemical progression of prostate cancer in patients who are undergoing active surveillance. One group was asked to complete 12 weeks of thrice-weekly, supervised aerobic sessions on a treadmill at 85% to 95% of peak oxygen consumption (V̇o2). The usual care group maintained their normal exercise levels.
Cardiology December 21st 2021